HC Wainwright Weighs in on Kairos Pharma FY2026 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Investment analysts at HC Wainwright issued their FY2026 earnings estimates for Kairos Pharma in a research note issued on Thursday, April 2nd. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.38) per share for the year. HC Wainwright also issued estimates for Kairos Pharma’s FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.73) EPS.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.07) EPS for the quarter.

Kairos Pharma Trading Down 4.3%

Shares of NYSEAMERICAN:KAPA opened at $0.59 on Tuesday. The company has a 50 day moving average of $0.61 and a 200 day moving average of $0.81. The stock has a market cap of $12.70 million, a P/E ratio of -1.98 and a beta of 1.97. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $2.11.

Hedge Funds Weigh In On Kairos Pharma

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in Kairos Pharma during the second quarter valued at approximately $44,000. Two Sigma Investments LP bought a new stake in Kairos Pharma during the third quarter valued at approximately $54,000. Finally, FNY Investment Advisers LLC bought a new stake in Kairos Pharma during the third quarter valued at approximately $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.